RC 101

12/01/2021 - "First, RC-101 robustly inhibited both Japanese encephalitis virus (JEV) and Zika virus (ZIKV) infections. "
10/01/2017 - "Finally, RC-101 decreased both the lethality and clinical severity associated with PR8 infection in mice. "
05/01/2007 - "The current study shows that RC-101, an analogue of retrocyclin, prevented HIV-1 infection in an organ-like construct of human cervicovaginal tissue and retained full activity in the presence of vaginal fluid. "
12/01/2007 - "Overall, these data suggest that most mutations capable of rendering HIV-1 resistant to RC-101 will also exert deleterious effects on the ability of HIV-1 to initiate infections - an interesting and novel property for a potential topical microbicide."
05/01/2007 - "Collectively, these data support the potential development of RC-101 as a topical microbicide to prevent HIV-1 infection and transmission."

12/01/2012 - "These dual properties, toxin inhibition and biofilm retardation, justify further exploration of RC-101 as a candidate agent for bacterial vaginosis prevention."
07/29/2011 - "Additionally, the effect of HVF on formulated RC-101 was evaluated with fluids collected from healthy volunteers, or from subjects with bacterial vaginosis (BV). "

08/14/2014 - "MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis."

12/01/2021 - "These findings provide a basis for the development of RC-101 as a potential candidate for the treatment of flavivirus infection. "

01/01/2022 - "As such, HNP1, as well as a θ-defensin retrocyclin RC-101, both interfere with Spike-mediated membrane fusion, Spike-pseudotyped lentivirus infection, and authentic SARS-CoV-2 infection in cell culture. "